Curaleaf (OTCMKTS:CURLF) versus PacificHealth Laboratories (OTCMKTS:PHLI) Financial Survey

Curaleaf (OTCMKTS:CURLF) and PacificHealth Laboratories (OTCMKTS:PHLI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a summary of current recommendations and price targets for Curaleaf and PacificHealth Laboratories, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curaleaf	0	0	1	0	3.00
PacificHealth Laboratories	0	0	0	0	N/A

Curaleaf presently has a consensus target price of $6.25, suggesting a potential upside of 100.71%. Given Curaleaf’s higher probable upside, equities research analysts clearly believe Curaleaf is more favorable than PacificHealth Laboratories.

Earnings & Valuation

This table compares Curaleaf and PacificHealth Laboratories”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curaleaf	$1.35 billion	1.50	-$281.20 million	($0.35)	-8.90
PacificHealth Laboratories	N/A	N/A	N/A	N/A	N/A

PacificHealth Laboratories has lower revenue, but higher earnings than Curaleaf.

Insider and Institutional Ownership

0.0% of Curaleaf shares are owned by institutional investors. 38.0% of PacificHealth Laboratories shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Curaleaf has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, PacificHealth Laboratories has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Profitability

This table compares Curaleaf and PacificHealth Laboratories’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Curaleaf	-18.59%	-14.75%	-5.19%
PacificHealth Laboratories	N/A	N/A	N/A

Summary

Curaleaf beats PacificHealth Laboratories on 5 of the 9 factors compared between the two stocks.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

About PacificHealth Laboratories

PacificHealth Laboratories, Inc. engages in the development of nutritional products that enhance health and athletic performance in the United States and internationally. It primarily focuses on sports performance, hydration, fueling, and muscle recovery. The company provides ENDUROX R4, a muscle recovery drink; ACCELERADE protein powered sports drink; ACCEL GEL, a energy gel; Body Glove Surge; ENDUROX EXCEL, an exercise supplement; and 2ND SURGE, an ultra energy gel. It also offers ACCELERADE HYDRO for less intense workouts use before, during, and after workouts for hydration, energy, and recovery. The company markets its products to various distribution channels, including sports specialty and natural product retailers and chains, as well as markets their products through its Website. PacificHealth Laboratories, Inc. was founded in 1995 and is based in Matawan, New Jersey.